SingVax Merges With Inviragen To Raise $15 Million In Series-A Financing For Vaccines To Fight Infectious Disease
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - U.S.-based Inviragen and Singapore-based SingVax unveiled plans to merge their companies' vaccine pipelines to form a new entity known as Inviragen (Singapore) to develop vaccines for a range of infectious diseases including dengue fever, Japanese encephalitis and hand, foot and mouth disease
You may also be interested in...
A vaccine project put on the shelf – after better-funded Intercell won regulatory approval for a rival product – has found a new home in Vietnam at a state-owned company looking to keep costs in check.